GlassScriptPhysician profile
John G Beauman
NPI 1497722441
$8,219.99
in general payments reported to CMS, 2019-2025
52 companies · $951 in 2025
The $951 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $1,079 · 2021: $1,443 · 2022: $1,080 · 2023: $1,538 · 2024: $1,085 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.04 | 2019-2025 | Ubrelvy, Qulipta, Synthroid |
| Astrazeneca Pharmaceuticals LP | $876.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $858.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $648.05 | 2019-2024 | Xarelto |
| Pfizer INC. | $634.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $590.41 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $320.88 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $256.22 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.46 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $242.62 | 2019-2024 | Eliquis |
| Astellas Pharma US INC | $169.70 | 2020-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $142.31 | 2022-2025 | |
| Grifols USA, LLC | $141.97 | 2019-2020 | |
| Lilly USA, LLC | $140.23 | 2021-2024 | Mounjaro, Trulicity |
| Eisai INC. | $121.83 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Beauman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.